2Su Z, Xu H, Zhang C, et al. Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance [J]. Croat Med J, 2006, 47: 410-415.
5Liou JM, Chang CY, Sheng WH, et al. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies [ J ]. Antimicrob Agents Chemother, 2011, 55: 1123-1129.
6Liou JM, Chen CC, Chang CY, et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial [J]. J Antimicmb Chemother, 2013, 68: 450-456.
7Monno R, Giorgio F, Carmine P, et al. Helicobacter pylori clarithromycin resistance detected by Etest and TaqMan real-time polymerase chain reaction : a comparative study [ J ]. APMIS, 2012, 120: 712-717.
9McCourt CM, McArt DG, Mills K, et al. Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis[ J]. PLoS One, 2013, 8 : e69604.
10Tuononen K, Maki-Nevala S, Sarhadi VK, et al. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin- fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS [ J ]. Genes Chromosomes Cancer, 2013, 52: 503-511.
